Work

Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.802

Authors: John Arthur Taylor, Shreyas Joshi, Raj Satkunasivam, Rian J. Dickstein, Amirali Salmasi, Yair Lotan, Scott Johnson, Raj Pruthi, Christine Tosone, Anne K. Schuckman, Jen-Jane Liu

Institutions: University of Kansas Medical Center, Emory University, Houston Methodist, University of California San Diego, The University of Texas Southwestern Medical Center, Medical College of Wisconsin, University of Southern California, Oregon Health & Science University

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407700812

Cites:

Cited by: 8

Related to: 10